查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1864074

靶向定序市場按產品類型、平台、最終用戶和應用分類－2025年至2032年全球預測

Targeted Sequencing Market by Product Type, Platform, End User, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，標靶定序市場將成長至 339.7 億美元，複合年成長率為 20.58%。

關鍵市場統計數據
基準年 2024 76億美元
預計年份：2025年 91.8億美元
預測年份 2032 339.7億美元
複合年成長率 (%) 20.58%

為決策者提供關於標靶定序的簡明策略指南，重點在於技術整合、臨床效用和營運影響。

化學、儀器和數據分析技術的進步使得標靶定序從一項小眾實驗室技術發展成為精準研究和臨床工作流程的基礎。本執行摘要總結了該技術的關鍵發展、應用模式、監管趨勢和競爭動態，旨在幫助研究機構、診斷實驗室和生命科學公司的管理人員制定策略重點和投資決策。

以下說明將標靶定序置於更廣泛的基因組學生態系統中，其中樣本處理能力、檢測特異性和生物資訊技術水平決定了其商業性和臨床應用的差異化。關鍵促進因素包括腫瘤學、遺傳性疾病診斷和感染疾病監測領域對精準基因組分析的需求，以及在常規工作流程中對經濟高效、高置信度變異檢測的需求。同時，不斷變化的監管要求和報銷機制也在影響檢測方法從研究到臨床實踐的轉化。

本導言將標靶定序定位為一個動態的模組化平台，其中儀器、耗材和軟體構成整合的端到端解決方案。它強調了互通性和工作流程最佳化的重要性，並指出了組織在平台選擇、面板設計和分析流程建構方面所面臨的策略選擇。本摘要的其餘部分詳細闡述了技術轉折點、外部政策影響、細分市場差異、區域績效差距，並為希望在這個快速成熟的領域創造價值的領導者提供了具體建議。

化學的進步、可擴展的儀器架構以及日益成熟的生物資訊學正在匯聚，重新定義靶向定序流程中的臨床和研究效用。

過去幾年，一系列變革正在重塑相關人員開發、部署和利用標靶定序解決方案的方式。首先，化學和樣品製備技術的創新縮短了周轉時間，提高了標靶效率，使診斷實驗室能夠提供更快、更可靠的結果。同時，儀器架構也實現了可擴展性，從用於分散式檢查的桌上型系統到用於集中式定序中心的高通量平台，拓展了其應用場景，從單例患者診斷擴展到大規模隊列研究。

同時，生物資訊學已從輔助角色發展成為一項策略能力。先進的變異檢測工具、標準化流程和可解釋的註釋層正在推動臨床層級的解讀，並縮短臨床醫生和研究人員的決策時間。軟體和服務日趨成熟，提高了提供整合分析服務的供應商的價值獲取，為訂閱和按效果付費的經營模式鋪平了道路。

市場動態也反映出向模組化生態系的轉變，在這個生態系中，試劑、套件和第三方分析工具可以共存。各機構越來越傾向於採用靈活的平台策略，將設備和試劑採購分離，以避免供應商鎖定，並保持檢測設計的靈活性。同時，定序提供者、試劑開發商和生物資訊公司之間更緊密的合作正在推動捆綁式解決方案的出現，從而加速醫院實驗室和研究中心對這些解決方案的採用。

監管和報銷環境也在影響產品設計和商業推廣。強調臨床療效和可追溯性的法規結構迫使醫療機構加強品管體系，產生可靠的檢驗數據，並儘早與監管機構溝通。同時，支付方開始要求提供更有力的臨床效用和成本效益證據才能實現廣泛應用，這促使研發人員調整其證據產生策略以適應報銷需求。這些變化共同重塑了該領域的競爭格局，並預示著未來不久資本和人才將更加集中。

2025 年關稅調整將促進目標定序生態系統的催化作用。

2025年美國關稅調整的累積影響已在目標定序價值定序中造成了顯著的摩擦，影響了籌資策略、定價和供應連續性。關稅相關的成本壓力影響了資本設備和耗材，並推高了進口到美國的儀器和試劑的到岸成本。因此，供應商和最終用戶重新評估了其採購計劃，並加快了供應商多元化，以維持營運預算和專案進度。

為因應這些貿易措施，許多供應商提高了生產在地化程度，具體做法包括將關鍵生產環節轉移到國內工廠，或在免稅區尋找替代供應商並進行資格認證。雖然這些調整緩解了進口關稅的即時影響，但也需要短期資本投資和供應鏈檢驗。一些試劑和套件生產商必須重新認證製造地並複製品管流程，導致前置作業時間延長和批次等效性評估，從而影響了產品供應。

除了製造地轉移之外，關稅環境也凸顯了供應鏈韌性的策略重要性。各組織更重視庫存緩衝、多供應商協議和合約保護，以降低上行風險。此外，採購部門擴大採用總到岸成本分析，該分析將關稅、合規相關費用和潛在延誤納入考量。這些措施使那些擁有地理位置分散的製造地和強大物流能力的供應商受益。

最後，關稅調整也影響了合作和商業性行為。隨著供應商和服務供應商尋求分擔本地化成本並確保優先獲得關鍵零件，戰略夥伴關係和共同投資模式日益受到重視。同時，一些學術和研究機構探索建立試劑共用聯盟和集中採購框架，以維持研究的連續性。雖然關稅增加了短期成本和營運複雜性，但也促進了供應鏈現代化，並激勵相關人員加強長期韌性策略。

基於深度細分的洞察，將產品架構、平台選擇、最終用戶優先順序和應用需求與策略決策流程連結起來。

細分市場分析清晰地區分了技術堆疊、使用者需求和商業性壓力，從而指南產品組合和市場推廣策略。根據產品類型，市場可分為儀器、試劑和套件以及軟體和服務。儀器部分涵蓋了從用於分散式和低通量檢測的桌上型定序儀到用於中心實驗室和大規模研究的高通量定序儀。試劑和套件包括基於擴增子、基於雜合反應和分子反轉探針的各種形式，每種形式都針對不同的標靶範圍、檢體類型和靈敏度要求進行了最佳化。軟體服務涵蓋生物資訊服務和數據分析軟體，反映了對數據解讀、流程檢驗和監管報告日益成長的需求。

平台細分進一步明確了技術權衡和應用適用性。擴增子定序工作流程，包括多重PCR和基於獨特分子識別碼（UMI）的方法，可為特定標靶和低起始量樣本提供高靈敏度。基於誘餌和探針的雜交捕獲策略可實現更廣泛的標靶覆蓋範圍，並提高複雜標靶的均一性。分子反轉探針專為高通量檢測而設計，其中包括針對拷貝數變異分析和單核苷酸多態性檢測最佳化的探針，可為標靶發現和基因型鑒定計劃提供經濟高效的擴充性。

終端用戶細分突顯了營運重點和採購模式的差異。學術研究機構（包括公立和私立研究機構）優先考慮方法的靈活性、發表級別的數據品質以及津貼主導的時間節點。醫院和診斷中心（包括就地檢驗和參考實驗室）優先考慮法規遵循、可重複性和臨床結果的快速交付。製藥和生物技術公司（包括臨床研究機構和藥物研發部門）優先考慮檢測方法的穩健性、擴充性臨床試驗以及與生物標記和伴隨診斷項目的整合。

應用細分突顯了驅動平台和合作夥伴選擇的多樣化用例。生物標記發現應用（涵蓋藥物基因組學和預測性生物標記）需要深度覆蓋和高註釋準確性。遺傳疾病工作流程（包括產前檢測和罕見疾病診斷）需要經過驗證、偽陰性率低且臨床報告清晰的檢驗。感染疾病應用（抗生素抗藥性檢測和病原體檢測）優先考慮能夠適應各種檢體基質的快速靈敏的檢測方法。腫瘤學應用（診斷、預後和治療診斷）需要靈活的檢測組合設計、與液態生物檢體的兼容性以及支援臨床決策的分析流程。了解這些細分領域之間的相互依存關係，有助於相關人員將產品開發、商業化和服務交付與明確的技術和臨床要求保持一致。

影響美洲、歐洲、中東和非洲以及亞太地區應用和商業化的區域趨勢和戰略要務：

區域趨勢差異顯著，影響美洲、歐洲、中東和非洲以及亞太地區的技術應用、監管策略和夥伴關係模式。在美洲，對診斷基礎設施的投資以及龐大的臨床研究基礎正在推動高通量平台和整合生物資訊解決方案的快速普及，這些方案支援轉化研究和集中式檢測網路。該地區的相關人員優先考慮與當地監管機構的監管協調、臨床檢驗和證據生成，以支持臨床應用和支付方參與。

歐洲、中東和非洲地區（EMEA）管理體制的差異和醫療保健資金籌措模式的不同導致了標靶定序應用路徑的差異。西方市場往往更注重互通性、標準化數據報告和品管系統，而該地區的新興市場則更關注可近性、能力建構和成本效益高的工作流程。公私合營舉措和區域參考實驗室網路在公共衛生和腫瘤學計畫中靶向定序的推廣應用方面發揮著至關重要的作用。

亞太地區正經歷產能的快速擴張，這主要得益於公共投資、龐大的病患群體以及雄心勃勃的精準醫療舉措。多個國家正大力投資於本地製造、國內研發和國家基因組計劃，加速了對用於分散式檢查的桌上型系統和用於人群規模研究的高通量平台的需求。在全部區域，全球供應商與本地服務供應商或製造商之間的夥伴關係正在推動技術轉移和人才培養，同時也有助於最佳化產品和服務，以滿足監管要求和價格敏感度。

在所有地區，跨國合作、數據協調和監管趨同正成為新興趨勢，推動了跨國臨床試驗和診斷工具的普及應用。區域基礎設施成熟度、支付方政策和本地生產能力持續影響供應商選擇和商業策略，凸顯了製定市場進入計畫時必須考慮區域差異的重要性。

在儀器、試劑和生物資訊學方面的專業知識，結合夥伴關係和服務模式，將決定永續的競爭優勢。

公司層面的趨勢反映了專業化、整合和服務差異化如何決定競爭定位。專注於儀器創新的供應商強調通量、自動化和從樣本到結果的工作流程，以減少人工操作時間並實現分散式檢查；而試劑和套件供應商則專注於檢測方法的穩健性、批間一致性以及與多個平台的易於整合，以最大限度地滿足各種應用場景的需求。

軟體和服務供應商正透過提供符合臨床解讀能力、監管合規性和實驗室認證要求的檢驗流程來脫穎而出。對於希望外包複雜分析並加速臨床部署的機構而言，託管服務、雲端分析和認證參考資料資料庫是關鍵的價值創造因素。儀器製造商和生物資訊公司之間的策略聯盟正在不斷擴大，以提供能夠縮短檢驗時間並提高客戶維繫的整合解決方案。

新興企業和專業服務供應商在利基創新領域發揮關鍵作用，它們開發新型化學方法、客製化捕獲探針以及針對難定序標靶的最佳化檢測方案。這些規模較小的營業單位通常與大型合作夥伴合作，以實現規模化生產和分銷，同時保持產品開發和客戶服務的靈活性。同時，受託研究機構(CRO) 和臨床 CRO 正在拓展其服務範圍，將標靶定序檢測方法開發和樣本管理服務納入其中，以滿足申辦者對端到端研究準備工作流程的需求。

總體而言，成功的公司會將卓越的技術與完善的品質系統、清晰的監管策略以及以客戶為中心的商業化模式相結合。隨著臨床和研究應用的不斷成熟，那些投資於證據生成、互通性和靈活商業結構的公司將更有利於獲取長期價值。

增強互通性、監管應對力、供應鏈韌性和實證商業化的實用策略重點

產業領導者應採取全面策略行動，以增強韌性、加速產品應用並抓住高價值機會。首先，應優先考慮平台互通性和開放標準，使客戶能夠以最小的阻力整合儀器、試劑和檢測方法，從而減少採購障礙並擴大目標用戶群。其次，應在產品生命週期的早期階段投資於監管和臨床證據建構能力，以加快臨床實用化速度並支持醫保報銷談判。

第三，我們將實現製造地和採購管道多元化，以降低關稅和地緣政治風險，同時確保關鍵耗材的穩定供應。此外，我們將開發靈活的商業模式，例如試劑即服務、訂閱式分析和按績效付費契約，使供應商的獎勵與客戶的營運和財務目標保持一致。第四，我們將加強與臨床實驗室、學術聯盟和製藥贊助商的合作，促進檢測組合的共同開發，並產生真實世界證據，以證明效用。

第五，我們將優先發展生物資訊學和檢測檢驗領域的人才，以維持高標準的分析水平，並加快客戶獲得洞見的速度。第六，我們將實施嚴格的品管系統和文件規範，以簡化監管申報流程，並促進多司法管轄區的核准。最後，我們將採用以互通性、病患隱私和安全雲端架構為重點的資料管治框架，以在確保合規性的同時，實現可擴展的分析。

綜合來看，這些努力創造了強大的競爭基礎，使產品藍圖與客戶需求、監管現實和營運限制保持一致，將技術能力轉化為永續的商業性成果。

採用混合方法的研究框架，結合相關利益者訪談、技術文獻綜述和監管審查，確保研究結果具有情境敏感度和可操作性。

本研究採用結構化訪談、技術檢驗審查和跨區域政策分析，整合一手和二手研究資訊，對靶向定序趨勢進行全面評估。研究人員與實驗室主任、檢測開發人員、採購人員和監管專家進行了初步的定性訪談，以了解營運挑戰、應用促進因素和證據生成策略。這些訪談有助於解讀不同平台架構之間的技術權衡，並為商業化和產品開發提供指南。

次要輸入資料包括同行評審文獻、監管指導文件、臨床路徑分析以及已發表的技術性能研究，這些研究說明了檢測的靈敏度、特異性和工作流程限制。該分析還利用了公開的臨床試驗註冊庫、專利申請和會議報告，以繪製創新軌跡並識別新興的化學技術和分析方法。一項比較政策審查評估了影響臨床應用的區域監管要求、品質標準和報銷框架。

此分析方法結合了定性綜合分析和技術特性、使用者需求及區域促進因素的交叉基準測試。在檢驗階段，研究人員將訪談結果與技術性能聲明和監管先例進行交叉核對，以確保結論反映實際應用。研究也承認其局限性，例如由於專有性能數據或商業保密協議的限制，部分內容的可見性受到限制。在適當情況下，研究建議重點強調了適用於各種證據和監管條件的靈活策略。

這種混合方法能夠產生可操作的、具有情境感知能力的見解，旨在支援研發規劃、商業策略和營運風險管理方面的決策。

整合策略要務和營運指導，將標靶定序的進步轉化為持續的臨床和商業性影響。

總之，標靶定序技術處於技術能力與臨床需求的策略交匯點，提供精準的基因組分析，以支援診斷、治療和公共衛生應用。化學、儀器和生物資訊學的進步正在拓展該技術的效用，並推動將檢測與綜合分析相結合的新型商業模式的出現。同時，監管預期、支付方審查和貿易政策等外部因素正在影響產品從研發到常規應用的轉換過程。

將產品開發與嚴謹的證據產生相結合、擁抱供應鏈多元化並優先考慮互通性的相關人員，將最有利於獲取持續價值。區域差異需要量身定做的應對措施：在監管和報銷體系支援規模化的地區，集中式高通量方法將更具優勢；而桌上型和分散式解決方案則能滿足快速照護現場決策的需求。最後，那些將卓越技術與周全的商業性和監管執行相結合的公司，將擁有最大的差異化優勢，並與診斷實驗室、醫療系統和製藥贊助商建立長期夥伴關係。

本執行摘要希望在不斷發展的標靶定序領域中優先考慮投資、設計合作項目和管理營運風險的領導者提供策略基礎。此處提出的建議和見解旨在支持嚴謹的決策，並將標靶定序創新快速轉化為可衡量的臨床和研究成果。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 快速整合客製化標靶定序面板，用於精準腫瘤學和個人化治療決策
  • 在臨床實驗室中擴大多重標靶定序檢測的規模，以實現對微生物病原體的全面檢測
  • 新興的單細胞標靶定序技術揭示腫瘤微環境中的細胞異質性
  • 引入長讀長標靶定序方法來檢測結構變異和複雜的基因組重排
  • 晶片上微流體靶向定序平台的發展，實現了高通量樣本處理和成本降低
  • 擴大標靶定序在非侵入性產前檢測的應用，以早期發現胎兒染色體異常
  • 生物資訊流程的進步提高了標靶定序資料分析工作流程的敏感度和特異性
  • 邁向整合標靶定序和數位病理解決方案，實現全面的分子診斷

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按產品類型分類的標靶定序市場

  • 裝置
    • 桌上型音序器
    • 高通量定序儀
  • 試劑和套件
    • 基於擴增子的套件
    • 雜合反應基礎試劑套件
    • MIP基礎套件
  • 軟體和服務
    • 生物資訊服務
    • 數據分析軟體

9. 按平台分類的標靶定序市場

  • 擴增子定序
    • 多重PCR
    • 基於UMI的定序
  • 混合捕獲
    • 餌料鱸魚捕獲
    • 基於探針的捕獲
  • 分子反轉探針
    • 用於 CNV 分析的 MIP 探針
    • 用於SNP檢測的MIP探針

第10章 按最終用戶分類的標靶定序市場

  • 學術和研究機構
    • 私人研究機構
    • 公共研究機構
  • 醫院和診斷中心
    • 就地檢驗實驗室
    • 參考實驗室
  • 製藥和生物技術公司
    • 臨床研究所
    • 藥物發現部

第11章 按應用分類的標靶定序市場

  • 生物標記發現
    • 藥物基因組基因生物標記
    • 預測性生物標記
  • 遺傳性疾病
    • 產前檢查
    • 罕見疾病診斷
  • 感染疾病
    • 抗生素抗藥性檢測
    • 病原體檢測
  • 腫瘤學
    • 診斷
    • 預後診斷
    • 治療診斷學

第12章 各地區的標靶定序市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 按組別分類的標靶定序市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國標靶定序市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • Agilent Technologies, Inc.
    • QIAGEN NV
    • F. Hoffmann-La Roche Ltd
    • BGI Genomics Co., Ltd.
    • Twist Bioscience Corporation
    • Pacific Biosciences of California, Inc.
    • Oxford Nanopore Technologies plc
    • NeoGenomics, Inc.
Product Code: MRR-1E2F1ED7E6A7

The Targeted Sequencing Market is projected to grow by USD 33.97 billion at a CAGR of 20.58% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.60 billion
Estimated Year [2025] USD 9.18 billion
Forecast Year [2032] USD 33.97 billion
CAGR (%) 20.58%

A concise strategic orientation to targeted sequencing highlighting technological integration, clinical utility, and operational implications for decision-makers

Targeted sequencing has evolved from a niche laboratory technique into a cornerstone of precision research and clinical workflows, driven by advances in chemistry, instrumentation, and data analytics. This executive summary synthesizes critical developments across technology, adoption patterns, regulatory dynamics, and competitive activity to support senior leaders in research organizations, diagnostics laboratories, and life sciences companies as they weigh strategic priorities and investment decisions.

The narrative that follows positions targeted sequencing within a broader genomics ecosystem where sample throughput, assay specificity, and bioinformatics sophistication now determine commercial and clinical differentiation. Key drivers include the demand for focused genomic interrogation in oncology, inherited disease diagnostics, and infectious disease surveillance, as well as the need for cost-efficient, high-confidence variant detection in routine workflows. At the same time, evolving regulatory expectations and reimbursement frameworks are shaping how assays translate from the bench to bedside.

This introduction frames targeted sequencing as a dynamic, modular platform space where instruments, consumables, and software integrate into end-to-end solutions. It underscores the importance of interoperability and workflow optimization while highlighting the strategic choices that organizations face when selecting platforms, designing panels, and building analytic pipelines. The rest of the summary elaborates on technological inflection points, external policy impacts, segmentation nuances, regional performance differentials, and actionable recommendations for leaders seeking to capture value from this rapidly maturing domain.

How chemistry advances, scalable instrument architectures, and maturing bioinformatics are jointly redefining clinical and research utility across targeted sequencing workflows

The past several years have produced transformative shifts that reshape how stakeholders develop, deploy, and monetize targeted sequencing solutions. First, chemistry and library-preparation innovations have compressed turnaround times and improved on-target efficiency, enabling diagnostics laboratories to deliver faster, higher-confidence results. These technical gains have been paralleled by instrument architectures that scale from benchtop systems for decentralized testing to high-throughput platforms for centralized sequencing hubs, thereby expanding the addressable use-cases from single-patient diagnostics to large-scale cohort studies.

Concurrently, bioinformatics has moved from a supporting role to a strategic capability. Sophisticated variant callers, standardized pipelines, and explainable annotation layers now drive clinical-grade interpretations and reduce time-to-decision for clinicians and researchers. This maturation of software and services increases the value capture for vendors offering integrated analytics and paves the way for subscription or outcome-linked commercial models.

Market dynamics also reflect a shift toward modular ecosystems where reagents, kits, and third-party analytical tools coexist. Organizations increasingly prefer flexible platform strategies that decouple instrument procurement from reagent sourcing to avoid vendor lock-in and maintain agility in assay design. At the same time, partnerships between sequencing providers, reagent developers, and bioinformatics firms have intensified, facilitating bundled solutions that accelerate adoption in hospital laboratories and research centers.

Regulatory and reimbursement landscapes are further influencing product design and commercial rollout. Regulatory frameworks that emphasize clinical validation and traceability have prompted providers to strengthen quality systems, produce robust validation datasets, and engage earlier with regulators. Meanwhile, payers are beginning to demand stronger evidence of clinical utility and cost-effectiveness for broad deployment, encouraging developers to align evidence-generation strategies with reimbursement needs. Taken together, these shifts are redefining the competitive logic of the field and guiding where capital and talent will concentrate in the near term.

How 2025 tariff adjustments catalyzed supply-chain resilience, localization investments, and strategic sourcing shifts across the targeted sequencing ecosystem

The cumulative impact of the United States tariff adjustments implemented in 2025 has introduced measurable friction across the targeted sequencing value chain, influencing sourcing strategies, pricing dynamics, and supply continuity. Tariff-related cost pressures have affected both capital equipment and consumables, elevating landed costs for instruments and reagents imported into the United States. As a result, providers and end users have recalibrated procurement plans and accelerated vendor diversification to maintain operational budgets and program timelines.

In response to these trade measures, many suppliers intensified efforts to localize production, either by shifting key manufacturing steps to domestic facilities or by qualifying alternative suppliers in tariff-exempt jurisdictions. These adjustments reduced immediate exposure to import levies but required short-term capital investments and supply-chain revalidation. For some reagent and kit manufacturers, the need to requalify manufacturing sites and to replicate quality-control processes introduced incremental lead times and batch equivalency assessments that impacted product availability.

Beyond manufacturing shifts, the tariff environment amplified the strategic importance of supply-chain resilience. Organizations placed greater emphasis on inventory buffering, multi-sourcing contracts, and contractual protection clauses to mitigate the risk of sudden cost escalation. Moreover, procurement teams increasingly incorporated total landed cost analyses that accounted for duties, compliance overhead, and potential delays. These practices favored suppliers with geographically distributed manufacturing footprints and robust logistics capabilities.

Finally, the tariff adjustments have influenced collaborative and commercial behaviors. Strategic partnerships and co-investment models gained traction as vendors and service providers sought to share localization costs and to secure preferential access to critical components. Concurrently, some academic and research institutions explored reagent sharing consortia and centralized procurement frameworks to preserve research continuity. While tariffs introduced near-term cost and operational complexity, they also catalyzed supply-chain modernization and encouraged stakeholders to strengthen long-term resilience strategies.

Deep segmentation-driven insights linking product architectures, platform choices, end-user priorities, and application requirements to strategic decision pathways

Segmentation analysis reveals distinct technology stacks, user needs, and commercial pressures that should guide portfolio and go-to-market strategies. Based on product type, the landscape separates into Instruments, Reagents & Kits, and Software & Services. Instruments span benchtop sequencers suited for decentralized, lower-throughput testing and high-throughput sequencers designed for central laboratories and large-scale studies. Reagents and kits include amplicon-based, hybridization-based, and molecular inversion probe formats, each optimized for different target breadths, sample types, and sensitivity requirements. Software and services cover bioinformatics services and data analysis software, reflecting the growing demand for interpretation, pipeline validation, and regulatory-grade reporting.

Platform segmentation further clarifies technical trade-offs and application fit. Amplicon sequencing workflows, including multiplex PCR and unique molecular identifier (UMI)-based approaches, deliver high sensitivity for focused panels and low-input samples. Hybrid capture strategies, realized through baits-based and probe-based capture formats, enable broader panel coverage and improved uniformity for complex targets. Molecular inversion probes are tailored for highly multiplexed detection and include probes optimized for copy-number variation analysis and single-nucleotide polymorphism detection, offering cost-efficient scalability for targeted discovery and genotyping projects.

End-user segmentation highlights differing operational imperatives and procurement patterns. Academic and research institutes, including both private research labs and public research labs, prioritize methodological flexibility, publication-grade data quality, and grant-driven timelines. Hospitals and diagnostic centers, encompassing point-of-care laboratories and reference laboratories, emphasize regulatory compliance, reproducibility, and rapid clinical turnaround. Pharmaceutical and biotechnology companies, including clinical research organizations and drug discovery units, focus on assay robustness, scalability for clinical trials, and integration with biomarker and companion diagnostic programs.

Application segmentation underscores the range of use-cases that drive platform choice and partner selection. Biomarker discovery applications, spanning pharmacogenomic and predictive biomarkers, require deep coverage and high annotation fidelity. Genetic disease workflows, including prenatal testing and rare disease diagnosis, demand validated assays with low false-negative rates and clear clinical reporting. Infectious disease applications-antibiotic resistance testing and pathogen detection-prioritize rapid, sensitive assays that accommodate diverse sample matrices. Oncology applications across diagnostics, prognostics, and theranostics require flexible panel design, compatibility with liquid biopsies, and analytical pipelines that support clinical decision-making. Understanding these segmentation interdependencies enables stakeholders to align product development, commercialization, and service offerings with clearly defined technical and clinical requirements.

Comparative regional dynamics and strategic imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific shaping adoption and commercialization

Regional dynamics vary substantially, shaping technology adoption, regulatory strategies, and partnership models across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, investment in diagnostic infrastructure, coupled with a large clinical research base, encourages rapid uptake of high-throughput platforms and integrated bioinformatics solutions that support translational research and centralized testing networks. Stakeholders in this region prioritize regulatory alignment with local authorities, clinical validation, and evidence generation to support clinical adoption and payer engagement.

Within Europe, Middle East & Africa, diverse regulatory regimes and varying healthcare funding models create differentiated adoption pathways. Western European markets tend to emphasize interoperability, standardized data reporting, and quality systems, while emerging markets in the region focus on access, capacity building, and cost-effective workflows. Collaborative public-private initiatives and regional reference laboratory networks play an outsized role in scaling targeted sequencing for public health and oncology programs.

Asia-Pacific demonstrates rapid capacity expansion driven by public investment, large patient populations, and ambitious precision-medicine initiatives. Several countries are investing heavily in localized manufacturing, domestic R&D, and national genomics programs, which accelerates demand for both benchtop systems for decentralized testing and high-throughput platforms for population-scale studies. Across the region, partnerships between global vendors and local service providers or manufacturers help tailor offerings to regulatory expectations and price sensitivity while advancing technology transfer and workforce development.

Across all regions, cross-border collaboration, data harmonization efforts, and regulatory convergence are emerging themes that support multinational clinical studies and diagnostic rollouts. Regional infrastructure maturity, payer policies, and local manufacturing capabilities continue to shape supplier selection and commercial strategies, underscoring the need for geographically nuanced go-to-market plans.

How specialization in instruments, reagents, and bioinformatics combined with partnerships and service models determines sustainable competitive positioning

Company-level trends reflect a competitive landscape where specialization, integration, and service differentiation determine positioning. Vendors focused on instrument innovation emphasize throughput, automation, and sample-to-answer workflows that reduce hands-on time and enable decentralized testing. Conversely, reagent and kit providers concentrate on assay robustness, lot-to-lot consistency, and ease of integration with multiple platforms to maximize addressable use cases.

Software and service providers are increasingly differentiating on clinical interpretive capabilities, regulatory readiness, and the ability to deliver validated pipelines that meet laboratory accreditation requirements. Managed services, cloud-enabled analytics, and certified reference databases have become important value levers for organizations seeking to outsource complex analytics or to accelerate clinical deployment. Strategic alliances between instrument manufacturers and bioinformatics firms have proliferated to offer bundled solutions that shorten validation timelines and improve customer retention.

Emerging companies and specialized service providers play a crucial role in niche innovation, developing novel chemistries, bespoke capture probes, and highly optimized panels for hard-to-sequence targets. These smaller entities often collaborate with larger partners for scale-up and distribution while retaining agility in product development and customer engagement. Meanwhile, contract research organizations and clinical CROs expand their offerings to include targeted sequencing assay development and sample management services, responding to sponsors' demand for end-to-end trial-ready workflows.

Overall, successful companies combine technical excellence with robust quality systems, clear regulatory strategies, and customer-centric commercialization models. Firms that invest in evidence generation, interoperability, and flexible commercial structures are better positioned to capture long-term value as clinical and research adoption continues to mature.

Practical strategic priorities for leaders to enhance interoperability, regulatory readiness, supply-chain resilience, and evidence-driven commercialization

Industry leaders should pursue a coordinated set of strategic actions to strengthen resilience, accelerate adoption, and capture higher-value opportunities. First, prioritize platform interoperability and open standards so that customers can integrate instruments, reagents, and analytics with minimal friction; this reduces buyer resistance and expands the addressable user base. Second, invest in regulatory and clinical-evidence capabilities early in the product lifecycle to shorten time-to-clinical utility and to support reimbursement discussions.

Third, diversify manufacturing and sourcing footprints to mitigate tariff and geopolitical risk while ensuring consistent supply for critical consumables. Coupled with this, develop flexible commercial models-such as reagent-as-a-service, subscription analytics, or outcome-linked agreements-that align vendor incentives with customers' operational and fiscal objectives. Fourth, strengthen partnerships with clinical laboratories, academic consortia, and pharmaceutical sponsors to co-develop panels and generate real-world evidence that demonstrates utility across diagnostic and therapeutic workflows.

Fifth, prioritize talent development in bioinformatics and assay validation to maintain high analytical standards and to accelerate time-to-insight for customers. Sixth, implement rigorous quality-management systems and documentation practices to streamline regulatory submissions and to facilitate multi-jurisdictional approvals. Finally, adopt a data governance posture that emphasizes interoperability, patient privacy, and secure cloud architectures to enable scalable analytics while preserving compliance.

Collectively, these actions create a durable competitive foundation by aligning product roadmaps with customer needs, regulatory realities, and operational constraints, enabling organizations to convert technical capabilities into sustainable commercial outcomes.

A mixed-methods research framework combining stakeholder interviews, technical literature synthesis, and regulatory review to ensure context-aware actionable insights

This research synthesizes primary and secondary inputs to generate a comprehensive assessment of targeted sequencing dynamics, drawing on structured interviews, technical validation reviews, and cross-regional policy analysis. Primary qualitative interviews were conducted with laboratory directors, assay developers, procurement leaders, and regulatory specialists to capture operational pain points, adoption drivers, and evidence-generation strategies. These conversations informed the interpretation of technical trade-offs across platform architectures and guided recommendations for commercialization and product development.

Secondary inputs included peer-reviewed literature, regulatory guidance documents, clinical-pathway analyses, and published technical performance studies that describe assay sensitivity, specificity, and workflow constraints. The analysis also leveraged publicly available clinical trial registries, patent filings, and conference proceedings to map innovation trajectories and to identify emerging chemistries and analytic approaches. Comparative policy reviews assessed regional regulatory expectations, quality standards, and reimbursement frameworks that influence clinical deployment.

Analytical approaches combined qualitative synthesis with cross-sectional benchmarking of technology attributes, user needs, and regional enablers. Validation steps included triangulating interview insights with technical performance claims and regulatory precedents, ensuring the conclusions reflect real-world implementation considerations. Limitations of the research are acknowledged where proprietary performance data or confidential commercial agreements restrict visibility; where appropriate, recommendations emphasize adaptable strategies that perform under varying evidentiary and regulatory conditions.

This mixed-methods approach produces actionable, context-aware insights intended to support decision-making across R&D planning, commercial strategy, and operational risk management.

Synthesis of strategic imperatives and operational guidance to translate targeted sequencing advancements into durable clinical and commercial impact

In conclusion, targeted sequencing occupies a strategic intersection between technological capability and clinical need, offering focused genomic interrogation that supports diagnostics, therapeutics, and public health applications. Advances in chemistry, instrumentation, and bioinformatics have expanded the technique's utility while driving new commercial models that couple assays with integrated analytics. At the same time, external forces-including regulatory expectations, payer scrutiny, and trade policy-shape how products move from development into routine use.

Stakeholders that align product development with rigorous evidence-generation, adopt supply-chain diversification, and prioritize interoperability will be best positioned to capture sustained value. Regional nuances require tailored strategies: centralized high-throughput approaches work well where regulatory and reimbursement systems support scale, while benchtop and decentralized solutions address demand for rapid, point-of-care decision-making. Finally, companies that combine technical excellence with thoughtful commercial and regulatory execution will find the greatest opportunities to differentiate and to secure long-term partnerships with diagnostic laboratories, healthcare systems, and pharmaceutical sponsors.

This executive summary provides a strategic foundation for leaders seeking to prioritize investments, design collaborative programs, and navigate operational risks in the evolving targeted sequencing landscape. The recommendations and insights herein are intended to support disciplined decision-making and to accelerate the translation of targeted sequencing innovation into measurable clinical and research impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid integration of custom targeted sequencing panels for precision oncology and personalized treatment decision making
  • 5.2. Expansion of multiplexed targeted sequencing assays for comprehensive microbial pathogen detection in clinical labs
  • 5.3. Emergence of single-cell targeted sequencing technologies to resolve cellular heterogeneity in tumor microenvironments
  • 5.4. Implementation of long-read targeted sequencing approaches to detect structural variants and complex genomic rearrangements
  • 5.5. Growth of on-chip microfluidic targeted sequencing platforms enabling high-throughput sample processing and reduced costs
  • 5.6. Increasing application of targeted sequencing in noninvasive prenatal testing for early detection of fetal chromosomal abnormalities
  • 5.7. Advancements in bioinformatic pipelines for enhanced sensitivity and specificity in targeted sequencing data analysis workflows
  • 5.8. Shift toward integrated targeted sequencing and digital pathology solutions for comprehensive molecular diagnostics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Targeted Sequencing Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Benchtop Sequencers
    • 8.1.2. High-Throughput Sequencers
  • 8.2. Reagents & Kits
    • 8.2.1. Amplicon-Based Kits
    • 8.2.2. Hybridization-Based Kits
    • 8.2.3. MIP-Based Kits
  • 8.3. Software & Services
    • 8.3.1. Bioinformatics Services
    • 8.3.2. Data Analysis Software

9. Targeted Sequencing Market, by Platform

  • 9.1. Amplicon Sequencing
    • 9.1.1. Multiplex PCR
    • 9.1.2. UMI-Based Sequencing
  • 9.2. Hybrid Capture
    • 9.2.1. Baits-Based Capture
    • 9.2.2. Probe-Based Capture
  • 9.3. Molecular Inversion Probes
    • 9.3.1. MIP Probes For CNV Analysis
    • 9.3.2. MIP Probes For SNP Detection

10. Targeted Sequencing Market, by End User

  • 10.1. Academic & Research Institutes
    • 10.1.1. Private Research Labs
    • 10.1.2. Public Research Labs
  • 10.2. Hospitals & Diagnostic Centers
    • 10.2.1. Point-of-Care Laboratories
    • 10.2.2. Reference Laboratories
  • 10.3. Pharmaceutical & Biotechnology Companies
    • 10.3.1. Clinical Research Organizations
    • 10.3.2. Drug Discovery Units

11. Targeted Sequencing Market, by Application

  • 11.1. Biomarker Discovery
    • 11.1.1. Pharmacogenomic Biomarkers
    • 11.1.2. Predictive Biomarkers
  • 11.2. Genetic Diseases
    • 11.2.1. Prenatal Testing
    • 11.2.2. Rare Disease Diagnosis
  • 11.3. Infectious Diseases
    • 11.3.1. Antibiotic Resistance Testing
    • 11.3.2. Pathogen Detection
  • 11.4. Oncology
    • 11.4.1. Diagnostics
    • 11.4.2. Prognostics
    • 11.4.3. Theranostics

12. Targeted Sequencing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Targeted Sequencing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Targeted Sequencing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Illumina, Inc.
    • 15.3.2. Thermo Fisher Scientific Inc.
    • 15.3.3. Agilent Technologies, Inc.
    • 15.3.4. QIAGEN N.V.
    • 15.3.5. F. Hoffmann-La Roche Ltd
    • 15.3.6. BGI Genomics Co., Ltd.
    • 15.3.7. Twist Bioscience Corporation
    • 15.3.8. Pacific Biosciences of California, Inc.
    • 15.3.9. Oxford Nanopore Technologies plc
    • 15.3.10. NeoGenomics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TARGETED SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. TARGETED SEQUENCING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. TARGETED SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TARGETED SEQUENCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TARGETED SEQUENCING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TARGETED SEQUENCING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BENCHTOP SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BENCHTOP SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BENCHTOP SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BENCHTOP SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BENCHTOP SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BENCHTOP SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HIGH-THROUGHPUT SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HIGH-THROUGHPUT SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HIGH-THROUGHPUT SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HIGH-THROUGHPUT SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HIGH-THROUGHPUT SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HIGH-THROUGHPUT SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON-BASED KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON-BASED KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON-BASED KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON-BASED KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON-BASED KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON-BASED KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRIDIZATION-BASED KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRIDIZATION-BASED KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRIDIZATION-BASED KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRIDIZATION-BASED KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRIDIZATION-BASED KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRIDIZATION-BASED KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP-BASED KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP-BASED KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP-BASED KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP-BASED KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP-BASED KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP-BASED KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY UMI-BASED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY UMI-BASED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY UMI-BASED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY UMI-BASED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY UMI-BASED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY UMI-BASED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BAITS-BASED CAPTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BAITS-BASED CAPTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BAITS-BASED CAPTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BAITS-BASED CAPTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BAITS-BASED CAPTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BAITS-BASED CAPTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROBE-BASED CAPTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROBE-BASED CAPTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROBE-BASED CAPTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROBE-BASED CAPTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROBE-BASED CAPTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROBE-BASED CAPTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR CNV ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR CNV ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR CNV ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR CNV ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR CNV ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR CNV ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR SNP DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR SNP DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR SNP DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR SNP DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR SNP DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR SNP DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRIVATE RESEARCH LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRIVATE RESEARCH LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRIVATE RESEARCH LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRIVATE RESEARCH LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRIVATE RESEARCH LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRIVATE RESEARCH LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PUBLIC RESEARCH LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PUBLIC RESEARCH LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PUBLIC RESEARCH LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PUBLIC RESEARCH LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PUBLIC RESEARCH LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PUBLIC RESEARCH LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY POINT-OF-CARE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY POINT-OF-CARE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY POINT-OF-CARE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY POINT-OF-CARE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY POINT-OF-CARE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY POINT-OF-CARE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DRUG DISCOVERY UNITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DRUG DISCOVERY UNITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DRUG DISCOVERY UNITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DRUG DISCOVERY UNITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DRUG DISCOVERY UNITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DRUG DISCOVERY UNITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACOGENOMIC BIOMARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACOGENOMIC BIOMARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACOGENOMIC BIOMARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACOGENOMIC BIOMARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACOGENOMIC BIOMARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACOGENOMIC BIOMARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY RARE DISEASE DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY RARE DISEASE DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY RARE DISEASE DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY RARE DISEASE DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY RARE DISEASE DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY RARE DISEASE DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ANTIBIOTIC RESISTANCE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ANTIBIOTIC RESISTANCE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ANTIBIOTIC RESISTANCE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ANTIBIOTIC RESISTANCE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ANTIBIOTIC RESISTANCE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ANTIBIOTIC RESISTANCE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY THERANOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY THERANOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY THERANOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY THERANOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY THERANOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY THERANOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2024 (USD MILLION)
  • TABLE 304. A